Top Logistics Stocks To Own For 2014

So if you put aside Rs.5000 a month, starting from your 35th birthday, then at the age of 55, assuming this investment grew by an average 7 percent p.a., your kitty would stand at Rs.25.5 lacs.

But if you start the same exercise now when you are 25, then the same kitty at age 55, would amount to a whopping Rs.58.8 lacs. Do you see the difference starting 10 years earlier can make? Isn’t this reason enough for you to put aside some money starting now?

So the Panchtantras, Aesop’s fables, Grandma’s tales, all knew what they were talking of when they preached that the ‘early bird gets the worm’. Now the next thing would be where to put this money every month?

Friends, do remember that money also has to bear the effect of inflation over time. So the purchasing power of money gets corroded and you end up having to pay more money in the future for the same thing. So when you are considering options for investment, you need to see the real return of the investment, not just the nominal return (face value). The real return takes into account the effect of inflation. Which is why, there is nothing more criminal in personal finance than leaving money idle in bank accounts. You earn a simple interest of 4% on your savings account. So at the end of the year your Rs.100 has now become Rs.104. Meanwhile the inflation for the year has been a low 5 percent i.e Rs.104 is actually worth Rs.98.90 in today’s term after inflation. Which means your real return on the Rs.100 is not Rs.4 but instead there is a loss of Rs.1.20 because of inflation.

Top Logistics Stocks To Own For 2014: Pernix Therapeutics Holdings Inc (PTX)

Pernix Therapeutics Holdings, Inc. (Pernix), incorporated in November 8, 1996, is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for pediatric and adult indications in a range of therapeutic areas. It manages a portfolio of branded and generic products and theobromine, a non-codeine, cough suppressant product candidate in development. The Company’s branded products for the pediatrics market include CEDAX, an antibiotic for middle ear infections, NATROBA, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC and a family of prescription treatments for cough and cold (BROVEX, ALDEX and PEDIATEX). It also markets REZYST IM, which is a probiotic blend to promote dietary management. Pernix markets generic products through its wholly owned subsidiary, Macoven Pharmaceuticals, LLC. In January 2013, the Company acquired Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc. In March 2013, the Company acquired Somaxon Pharmaceuticals Inc. In September 2013, Pernix Therapeutics Holdings, Inc. completed the sale of certain non-core assets to Breckenridge Pharmaceutical, Inc.

The Company’s customers consist of drug wholesalers, retail drug stores, mass merchandisers and grocery store pharmacies in the United States. It primarily sells products directly to drug wholesalers, which in turn distribute the products to retail drug stores, mass merchandisers and grocery store pharmacies.

ALDEX Line

ALDEX is a line of antihistamines, decongestants and cough suppressants that are indicated for the temporary relief of respiratory allergies, allergic rhinitis and symptoms of the common cold. The Company’s ALDEX product line is marketed in a range of formulations and combinations using different drug-delivery methodologies to target specific segments of the antihistamine, decongest ant and cough suppressant markets. Two used decongestants ar! e phenylephrine and pseudoephedrine.

BROVEX Line

The BROVEX line is a line of antihistamine combinations with the active pharmaceutical ingredient (API) brompheniramine maleate, part of the first generation class of antihistamines called alkylamines that are indicated for the temporary relief of sneezing, itchy, watery eyes, itchy nose or throat, and runny nose due to hay fever or other respiratory allergies. Its BROVEX product line is marketed in a range of formulations and combinations to target specific segments of the antihistamine market. The Company completed the conversion of the BROVEX product family to over-the-counter (OTC) monograph from DESI drugs, in April 2011.

CEDAX Line

CEDAX is a third generation oral cephalosporin indicated for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza or streptococcus pyogenes. The Company sells a range of dosages utilizing both capsule and oral suspension drug delivery methodologies. It also owns a trademark on the name CEDAX in the United States.

NATROBA Line

NATROBA Topical Suspension is a prescription medicine used to treat head lice (pediculosis capitis) in adults and children four years of age and older. NATROBA contains the active ingredient spinosad, which is derived from a naturally occurring soil bacterium.

PEDIATEX Line

As of December 31, 2011, the only product that the Company marketed and sold in its PEDIATEX line is PEDIATEX TD. PEDIATEX TD is an antihistamine/nasal decongestant combination liquid for oral administration. Each 1 milliliter dose contains the API Tripolidine HC1 and Pseudoephedrine HC1. Tripolidine HC1 is a first generation antihistamine in the alkylamine class. Pseudoephedrine, a decongestant, is a sympathomimetic, which acts on alpha-adrenergic receptors in the mucosa of the respirat ory tract, producing vasoconstriction and having minimal eff! ect on be! ta-receptors. It therefore functions as an oral nasal decongestant with minimal central nervous system stimulation.

REZYST Line

REZYST IM is a probiotic blend that promotes the dietary management of patients with the distinctive nutritional requirements associated with the gastro-intestinal flora. It is formulated to improve the digestive health of patients by replacing the active cultures altered by diet, stress, and antibiotics.

Product Candidates in Development

Product candidates in development include Theobromine. Theobromine is an alkaloid naturally present in dark chocolate which is an existing human metabolite of caffeine. The Company is working on several other product candidates, which includes a prescription product for the pediatrics market. In March 2012, the Company entered into a product development agreement with a private company for this product.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Leading and Lagging Sectors
    Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Horizon Pharma (NASDAQ: HZNP) and Pernix Therapeutics Holdings (NASDAQ: PTX). In trading on Wednesday, telecommunications services shares were relative laggards, down on the day by about 0.39 percent. Top decliners in the sector included Shenandoah Telecommunications Co (NASDAQ: SHEN), off 3.3 percent, and CalAmp (NASDAQ: CAMP), down around 2.4 percent.

Top Logistics Stocks To Own For 2014: Pennsylvania Real Estate Investment Trust (PEI)

Pennsylvania Real Estate Investment Trust (PREIT), incorporated on September 29, 1997, is a fully integrated, self-managed and self-administered real estate investment trust (REIT). The Company has a primary investment focus on retail shopping malls located in the eastern half of the United States, primarily in the Mid-Atlantic region. As of December 31, 2012, the Company owned interests in 46 retail properties, of which 42 were operating properties, three were development properties and one was classified as held for sale. The 42 operating properties, which are classified in continuing operations, include 36 enclosed malls and six strip and power centers, have a total of 30.7 million square feet and operate in 12 states. The Company and partnerships in which the Company owns an interest owned 23.9 million square feet at these properties (excluding space owned by anchors). The development portion of the Company’s portfolio contains three properties in two states, with two classified as mixed use (a combination of retail and other uses) and one classified as other. In January 2013, the Company sold its interests in Paxton Towne Centre in Harrisburg, Pennsylvania and Phillipsburg Mall in Phillipsburg, New Jersey. In February 2013, the Company sold Orlando Fashion Square in Orlando, Florida. In November 2013, the Company sold Chambersburg Mall in Chambersburg, PA.

As of December 31, 2012, the Company had four properties, which were classified as held for sale, two of which were malls and two of which were power centers. The Company is engaged in the ownership, management, leasing, acquisition, redevelopment and development of enclosed malls. The Company’s malls include national or regional department stores, large format retailers or other anchors and a diverse mix of national, regional and local in-line stores offering apparel (women’s, family, teen, children’s, men’s), shoes, eyewear, cards and gifts, jewelry, sporting goods, hom e furnishings, drug stores, electronics and books/music/movi! es, among other things. Its malls have restaurants and/or food courts, and some of the malls have multi-screen movie theaters and other entertainment options, either as part of the mall or on outparcels around the perimeter of the mall property. In addition, its malls have outparcels containing restaurants, banks or other stores. It derives its revenue from rent received under leases with tenants for space at retail properties in its real estate portfolio.

Advisors’ Opinion:

  • [By Marc Bastow]

    Retail shopping mall real estate investment trust Pennsylvania REIT (PEI) raised its quarterly dividend 11% to 20 cents per share, payable on Dec. 16 to shareholders of record as of Dec. 2.
    PEI Dividend Yield: 4.74%

  • [By Rich Duprey]

    Pennsylvania Real Estate Investment Trust  (NYSE: PEI  )  reported first-quarter results yesterday that were below consensus expectations on the top line but came in ahead on the bottom line, causing the company to raise guidance for the full year.

Top Logistics Stocks To Own For 2014: Braskem SA (BRKM5)

Braskem SA is a Brazil-based company primarily engaged in the manufacture of basic petrochemical products. The Company operates in five segments: Basic petrochemicals, Polyolefins, Vinyls, International businesses and Chemical Distribution. The Company’s products portfolio includes ethylene, propylene, butadiene, toluene, xylene, benzene, gasoline, diesel oil, liquefied petroleum gas (LPG), as well as thermoplastic resins, such as polyethylene (PE), polypropylene (PP) and polyvinyl chloride (PVC). Additionally, Braskem is also engaged in the import and export of chemicals, petrochemicals and fuels; the production, supply and sale of utilities, such as steam, water, compressed air, industrial gases, as well as the provision of industrial services, and the production, supply and sale of electric energy for its own use and use by other companies. The Company also invests in other companies, either as a partner or shareholder. Advisors’ Opinion:

  • [By Harry Suhartono]

    Brazil’s Ibovespa rose for a third day as traders pared bets on higher borrowing costs in Brazil, boosting the outlook for companies that sell in the local market. B2W Cia. Digital led gains among retailers, with Lojas Americanas SA (LAME3) and Natura Cosmeticos SA (NATU3) also trading higher. Petrochemicals producer Braskem SA (BRKM5) was the worst performer on the equity gauge after O Estado de S.Paulo reported Petroleo Brasileiro SA (PETR4) is seeking to raise prices of naphtha sold to the company by 5 percent.

Top Logistics Stocks To Own For 2014: Gazprom OAO (GAZP)

Gazprom OAO is a Russia-based company engaged in the operation of gas pipeline systems and gas supply to European countries. In addition, it is involved in the oil production and refining activities, as well as energy generation. It’s activities comprise exploration and production of gas, transportation of gas, sale of gas domestically and abroad, gas storage, production of crude oil and gas condensate, processing of oil, gas condensate and other hydrocarbons, and sales of refined products, as well as electric and heat energy generation and sales. On January 9, 2013, the Company sold its 76.69% stake in Zapsibgazprom OAO and whole stake in March Kauno termofikacijos elektrine. In April 2013, it also created Gazprom Invest LLC, as well as, signed a purchase-sale contract for shares in 72 gas distribution organizations belonging to Rosneftegaz OAO. In November 2013, the Company raised its stake to 100% in CJSC Gazprom Neft Orenburg. Advisors’ Opinion:

  • [By Ian Sayson]

    Russian stocks fell for a third day as crude oil, the nation’s chief export earner, retreated. Mechel fell to the lowest level since Sept. 6, while OAO Gazprom (GAZP), the natural-gas export monopoly, retreated 0.9 percent.

Top Logistics Stocks To Own For 2014: Weis Markets Inc.(WMK)

Weis Markets, Inc. engages in the retail sale of food in Pennsylvania and surrounding states. Its retail food stores sell groceries, dairy products, frozen foods, meats, seafood, fresh produce, floral, pharmacy services, deli products, prepared foods, bakery products, beer and wine, fuel and general merchandise items, such as health and beauty care, and household products. The company operates stores primarily under the Weis Markets trade name. As of February 13, 2012, it operated 161 stores in Pennsylvania, Maryland, New York, New Jersey, and West Virginia. The company was founded in 1912 and is based in Sunbury, Pennsylvania.

Advisors’ Opinion:

  • [By Rich Duprey]

    Mid-Atlantic grocery store chain Weis Markets (NYSE: WMK  ) announced yesterday its third-quarter dividend of $0.30 per share, the same rate it’s paid for the past six quarters.

Top Logistics Stocks To Own For 2014: Hurco Companies Inc. (HURC)

Hurco Companies, Inc., an industrial technology company, engages in the design, manufacture, and sale of computerized machine tools, computer control systems, and software products to companies in the metal working industry primarily in North America, Europe, and Asia. The company offers general purpose computerized machine tools, such as vertical machining centers/mills and turning centers/lathes. It also provides computer control systems and related software for press brake applications. In addition, the company produces and distributes software options, control upgrades, hardware accessories, and replacement parts for its machine tool product lines, as well as provides operator training and support services to its customers. Hurco Companies, Inc. offers its products to the precision tool, die, and mold manufacturers; independent metal parts manufacturers; and specialized production application or prototype departments within manufacturing operations. It serves aerospace , defense, medical equipment, energy, automotive/transportation, electronics, and computer industries. The company sells its products through independent agents and distributors in North America, Europe, and Asia, a swell as through direct sales personnel in Canada, China, France, Germany, Italy, Poland, Singapore, South Africa, Spain, the United Kingdom, and certain parts of the United States. Hurco Companies, Inc. was founded in 1968 and is headquartered in Indianapolis, Indiana.

Advisors’ Opinion:

  • [By John Emerson]

    Hardinge (HDNG) the Perfect Fit to the Investment Puzzle

    Several years earlier I had started following the machine tool sector and I became quite familiar with Hardinge. Although I never invested in the stock (I had opted for Hurco), I had noted that Jeffrey Gendell had been purchasing shares the company. Hurco (HURC) had much higher margins and it was my belief that the superior quality of their computerized machine tools and their accompanying software were reflected in their earnings. Hurco also held a vastly superior balance sheet at the time I made my investment.

Top Logistics Stocks To Own For 2014: EnteroMedics Inc.(ETRM)

EnteroMedics Inc., a clinical development stage medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity and associated co-morbidities, and other gastrointestinal disorders. The company?s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. Its product under development is the Maestro System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company intends to market its products to potential referral source clinicians, including general practitioners, internists, endocrinologists, and nurses. It has collaboration agreement with Mayo Clinic and Australian Institute of Weight Control. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003 . EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

Advisors’ Opinion:

  • [By John Udovich]

    On Tuesday, small cap EnteroMedics Inc (NASDAQ: ETRM) soared 63.5% after reporting new clinical trial data for its Maestro system that is designed to control obesity, meaning it might be time to take a closer look at the stock along with the performance of other small cap obesity drug or treatment players like Arena Pharmaceuticals, Inc (NASDAQ: ARNA), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS).

  • [By John Udovich]

    Small cap biotech Arena Pharmaceuticals, Inc (NASDAQ: ARNA) soared yesterday and last Friday on earnings as well as news that the company will expand its marketing and supply agreement with Japan based Eisai for its BELVIQ (lorcaserin HCl) obesity drug, meaning it might be time to take a closer look at other biotech stocks like Orexigen Therapeutics, Inc (NASDAQ: OREX), EnteroMedics Inc (NASDAQ: ETRM) and VIVUS, Inc (NASDAQ: VVUS) that are in the business of treating obesity. Specifically, Arena Pharmaceuticals announced an expanded agreement providing Eisai with exclusive commercialization rights for all countries worldwide (except for South Korea, Taiwan, Australia, Israel and New Zealand) for BELVIQ where Arena will receive an upfront payment of $60 million and is eligible to receive up to a total of $176.5 million in regulatory and development milestone payments – an increase of $123 million from the amount remaining available under the previous agreement. BELVIQ was a pproved in June 2012, but didn’t reach the market until June 2013 due to logistical concerns like classification by the Drug Enforcement Administration. Its also approved for use in adults who are obese or who are overweight and who have at least one serious medical condition (e.g. diabetes or high cholesterol).

Top Logistics Stocks To Own For 2014: Nuvilex Inc (NVLX)

Nuvilex, Inc., incorporated on October 28, 1996, operates independently and through wholly owned subsidiaries. The Company is a biotechnology and life technology company with a specialty in living-cell encapsulation. It is focused on preparations for a new pancreatic cancer clinical trial through live-cell encapsulation of chemotherapeutic-converting cells. It has created the hardware and operating platform to envelop or encapsulate its own or other company’s software products, or cells. These cells are then packaged in its live cell encapsulation operating system. Its products include Cinnechol, Cinnergen, Cinnsational, Citroxin, Cyclosurface, Cosmetics, Infinitink, Talsyn, Oraphyte and PurEffect. On July 10, 2013, the Company acquired Bio Blue Bird AG. In November 2013, the Company announced that it has acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes from SG Austria Pte. Ltd.

Cinnechol

Cinnechol is a gluten free/wheat free all-natural supplement designed to help maintain normal cholesterol levels and support normal cardiovascular function through a healthy diet and regular exercise and to help individuals manage cardiovascular and metabolic disorders. Cinnechol may provide a natural alternative for those with high cholesterol and intolerant of, or elect not to take statins.

Cinnergen

Cinnergen is a gluten free/wheat free all-natural liquid whole food nutritional supplement that provides nutrients to help the body efficiently process glucose, is made from natural ingredients. Clinical studies using Cinnergen, as well as peer reviewed research suggest constituents of Cinnergen may help to reduce glucose absorption in the small intestine, limit glucose synthesis and increase its metabolism and prevent conditions associated with pre-diabetes or diabetes types one and two by delivering amino a cids, vitamins, minerals, enzymes, antioxidants, and plant b! ased extracts to the body thus helping control glucose levels.

Cinnsational

Cinnsational is a gluten free/wheat free all-natural calorie-free, liquid nutritional supplement contains concentrated blend vitamins, essential amino acids, and other beneficial ingredients to help the body combat symptoms associated with alcohol sensitivity, including nausea, fatigue and headaches.

Citroxin

Citroxin is an all-natural, eco-friendly surface cleaner. Citroxin is protected by patents in the United States and Thailand.

Cyclosurface Cosmetics

Nuvilex’s Cyclosurface color enhancement technology provides formulators and manufacturers of cosmetics and other consumer products the ability to use less wax and other potentially detrimental additives in their products through a lipophilic surface treatment. It improves pigment dispersion enabling products that feel lighter on the skin and make the skin look radiant while maintaining or enhancing the color and durability of the cosmetic product.

I-Boost Immune Bar

I-Boost Immune Bar is a gluten free/wheat free all-natural nutritional bar designed to protect, stimulate, and boost the immune system. It was reformulated and contains a blend of vitamins, minerals, and other ingredients designed to enhance the body’s natural ability to defend itself.

Infinitink

Infinitink is a permanent, yet removable tattoo ink, was engineered specifically for removal in fewer laser treatments than standard tattoo ink. Typically, lasers used for removal of tattoos use 532 and 1064 nanometer wavelengths which closely match the Infinitink tattoo pigments, enabling more easily removed tattoos.

Oraphyte

Oraphyte is the Company’s all-natural nematocide, is a non-toxic, biodegradable formulation that damages a nematode’s skin surface, compromising its immune system, enabling it to be killed by the environment. In field tests, Oraphyte reduced! problema! tic nematodes, parasitic plant worms found in soil, compared to non-treated controls.

purEffect

PurEffect is a three part, all-in-one acne treatment designed to cleanse, tone, and heal skin combining ingredients to help maintain a radiant, blemish-free complexion. Benzoyl peroxide, the active ingredient in purEffect is the safest, recommended ingredient used to treat acne. This line of products completed pre-marketing testing by CK41.

Specialty, Private Label Inks

The Company has the potential to manufacture specialty inks for private label customers derived from the Company’s Virgin and Infinitink product lines and are formulated to specific customer needs. The Company’s specialty inks are formulated to be all natural, heavy metal and toxin-free.

Talsyn Scar Cream

Talsyn Scar Cream is a cream that delivers lipids, peptides, and botanical extracts to the skin. It was clinically proven to improve appearance of keloids, surgical incisions, and scars through decreasing their width, length, depth, and redness for both old and new scars. Talsyn Scar Cream has been endorsed and used by plastic and reconstructive surgeons.

Advisors’ Opinion:

  • [By Bryan Murphy]

    Though they’ve been lumped into the same category as Medical Marijuana Inc. (OTCMKTS:MJNA) and Tranzbyte Corp. (OTCMKTS:ERBB), names like Nuvilex Inc. (OTCMKTS:NVLX) and Growlife Inc. (OTCBB:PHOT) aren’t actually marijuana stocks. Granted, PHOT and ERBB shareholders will benefit from the advent of legalized marijuana (and hemp) as much as shareholders of ERBB – a grower and dispenser – and MJNA shareholders will. But, in some way they’re safer and more stable because they’re not directly in the line of fire of potential regulation… or better-enforced regulation at the federal level. Indeed, there are several stocks that are circumventing the risk inherent with marijuana stocks, because they’re not marijuana stocks at all. They are, in no particular order….

  • [By James E. Brumley]

    Cancer drug investors who have been disappointed in recent results from shares of Clovis Oncology Inc. (NASDAQ:CLVS) or Nuvilex Inc. (OTCMKTS:NVLX) lately may want to take a look at ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as a replacement for either of those first two stocks. CLVS is down about 16% for the week on a less-than-flattering write-up in a Bloomberg publication, and NVLX has moved under a pair of key moving averages this week because, well, for no specific reason, but broadly because the recent wave of compelling news is already losing its potency, with most of that upside already being priced into shares (and then some) before it became official.

Top Logistics Stocks To Own For 2014: ONYX Pharmaceuticals Inc.(ONXX)

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., develops and markets Nexavar (sorafenib) tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of kidney, liver, lung, thyroid, breast, and non-small cell lung cancers; clinical trials on carfilzomib, a proteasome inhibitor for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors; and Phase Ib/II clinical trial on Oprozomib, an oral proteasome inhibitor. In addition, Onyx Pharmaceuticals, Inc. is developing ONX 0914, an immunoproteasome inhibitor, which is in preclinical stage for the treatment of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, and lupus. Further, the company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals, Inc., is conducting clinical trials on Regorafenib, a multi-kinase inhibitor to treat metastatic colorectal cancer and gastrointestinal stromal tumors. It has a collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore control of or intervene in the misregulated cell cycle in tumor cells. The company also has development and license agreements with BTG International Limited for the development and commercialization of ONX 0801, a novel targeted oncology compound; and Ono Pharmaceutical Co., Ltd. to develop and commercialize carfilzomib and Oprozomib for oncology indications in Japan. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in South San Francisco, California.

Advisors’ Opinion:

  • [By Steven Silver]

    To bolster growth, Amgen secured FDA approval of its denosumab franchise in 2010 for post-menopausal osteoporosis, as well as for cancer-related bone loss. In October 2013, Amgen acquired Onyx Pharmaceuticals (ONXX) to expand into the lucrative cancer treatment markets.

  • [By MONEYMORNING]

    Add Amgen Inc.’s (Nasdaq: AMGN) August $10.4 billion offer for Onyx Pharmaceuticals Inc. (Nasdaq: ONXX), Perrigo Co.’s (NYSE: PRGO) July purchase of Elan Corp. (NYSE ADR: ELN) for $8.6 billion, and the Shire deal, and the year-to-date deal value for pharma/biotech M&A hits more than $50 billion.

  • [By Kyle Anderson, Associate Editor – November 12th, 2013 Money Morning]

    Here’s the list of top 10 “cash-rich” companies in the S&P 500, based on cash, cash equivalents, and short-term investments, plus how they used the cash they did spend:

    General Electric Co. (NYSE: GE) reported cash and cash equivalents of $130.3 billion in September 2013, down slightly from $132.4 billion in June and $138 billion in March. Currently, GE offers its shareholders a dividend of $0.76 per year, or 2.8%. Early in 2013, it was reported that GE planned on buying back $10 billion of its stock from investors. The buyback was prompted by GE selling 49% stake in NBC Universal to Comcast Corp in March. In April, GE acquired the Texas-based oil company Lufkin Industries for $3.3 billion. Microsoft Corp. (Nasdaq: MSFT) had a total of $80.6 billion in cash and short-term investments at the end of September. This was the fourth consecutive quarter of growth for the company that reported $77 billion in June, $74.4 billion in March, and $68.2 billion in December 2012. MSFT provides its shareholders with a 3% dividend, or $1.12 per year. In September, MSFT made headlines for its $40 billion stock buyback and 22% dividend increase. In the same month, Microsoft completed a $7.2 billion acquisition of Nokia Corp.’s (NYSE: NOK) cellphone business. Google Inc. (Nasdaq: GOOG) is third with a cash and short-term investment hoard of $56.4 billion as of September. Google is another company that has added to its cash total in recent quarters, reporting $54.3 billion in June and $50.0 billion in March. Despite all that cash, GOOG does not issue a dividend and has never offered a shareholder buyback. The search engine mogul has a long history of acquisitions, and its purchase of Israeli navigation software Waze, for just shy of $1 billion in June 2013, was its largest in several years. Cisco Systems Inc. (Nasdaq: CSCO) had $50.5 billion in its July statement, compared to $47.3 billion and $46.3 billion in the previous two quar

  • [By Sean Williams]

    Tivozanib is an oral, once-daily treatment for metastatic renal cell carcinoma that works by blocking three VEGR-receptors that are critical for blood vessel growth development for solid renal cell tumors, and is being targeted as a first-line treatment. In trials, AVEO and its partner Astellas Pharma went head-to-head against Onyx Pharmaceuticals’ (NASDAQ: ONXX  ) Nexavar and delivered good, but not groundbreaking, results. In its TIVO-1 study, released last year, Tivozanib met its primary progress-free survival endpoint and delivered a median PFS of 11.9 months compared with the median PFS of just 9.1 months for Nexavar. The difference was even more pronounced in treatment-naive patients where the PFS difference grew to 12.7 months as compared to 9.1 months for Nexavar. However, overall survival rates for AVEO’s drug actually were slightly lower than Nexavar over the course of the study.  

Top Logistics Stocks To Own For 2014: Mitel Networks Corporation(MITL)

Mitel Networks Corporation provides integrated communications solutions to the small-to-medium sized enterprise market in the United States, Europe, the Middle East, Africa, Canada, Caribbean, Latin America, and the Asia Pacific. It offers Internet protocol (IP) telephony platforms, including IP telephony software that performs various functions comprising multi-media call control and communications, which allow business users to reach each other, share information, and collaborate; appliances; and desktop devices, such as IP and digital phones, specialty desktop devices, and peripherals. The company also provides a suite of UCC applications, which consist unified communicator advanced, mobility, customer interaction solution, unified messaging, speech auto attendant, telecollaboration solution, teleworker solution, and business dashboard, as well as audio, video, and Web conferencing for integrating voice, video, and data communications with business applications. In addi tion, it offers network services that include local access services; long distance services; mobile voice and data services; data services, such as Internet access and private networking services; hosted offerings, which comprise network monitoring and management, audio conferencing, Web conferencing, hosted secure Internet access, and Web hosting; and hosted IP telephony services. Further, the company provides managed services, including project management, installation, training, maintenance, professional, consulting, business requirements review, and disaster recovery planning services; support services; and financing of its solutions. It serves education, government, healthcare, hospitality, and retail markets through wholesale distributors, solution providers, system integrators, authorized channel partners, and other technology providers. The company is headquartered in Ottawa, Canada.

Advisors’ Opinion:

  • [By Michael Robinson]

    Mitel Networks (MITL)

    Small-cap Mitel is known for its advanced contact center platform that includes mobile chat and also helps mid-market firms generate sales leads while lowering expenses.

  • [By MONEYMORNING.COM]

    Mitel Networks Corp. (Nasdaq: MITL) is a small-cap communication and collaboration software company that caters to small and medium-sized businesses.

  • [By Richard Lomas]

    How much impact there will be on the profit margin will depend on the royalty rate set. Virnetx has an established royalty rate structure both published and through agreements with other licensees. Virnetx’s published royalty rate is between 1 and 2 percent for customers in good standing. This royalty rate has been validated through licenses with 4 different companies, Siemens (SI), NEC, Mitel (MITL), and Aastra (AATSF.PK). The average rate agreed to by these companies through negotiations is 1.52%, right in the middle of the 1 to 2 percent published rate. Whatever rate is set will further reduce Apple’s profit margin.